Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304847 | 1.00 | MEN1 (0.41) | MEN1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL14117916 | 0.82 | ATM (0.45) | KMT2AALDH1A1ATMNR1H2CHRM2 | |
| SCHEMBL13765329 | 0.80 | MEN1 (0.36) | MEN1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL19637269 | 0.79 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL7925515 | 0.78 | GPR119 (0.54) | GPR119 | |
| SCHEMBL13765421 | 0.78 | ABCB1 (0.37) | MEN1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL18849728 | 0.77 | ATM (0.50) | MEN1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL3844539 | 0.76 | NR1H2 (0.46) | MEN1KMT2AALDH1A1ATMHSD17B10 | |
| SCHEMBL12264685 | 0.76 | NR1H2 (0.45) | MEN1KMT2AALDH1A1HSD17B10NR1H2 | |
| SCHEMBL19616387 | 0.76 | NR1H2 (0.45) | MEN1KMT2AALDH1A1HSD17B10NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187419-B2 | Intermediates of sitagliptin and preparation process thereof | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20130281695-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281695-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | DPP4, DPP9, DPP3 | MEN1 2044/4885KMT2A 1823/4885ALDH1A1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.